Tag
Healthy dietary patterns may reduce intracranial atherosclerosis severity in older adults with hypertension or prior myocardial infarction, suggesting diet’s conditional protective role in vascular brain disease.
This meta-analysis reveals that β-blocker therapy reduces mortality and adverse cardiovascular events in myocardial infarction patients with mildly reduced left ventricular ejection fraction (40–49%), extending benefits beyond reduced LVEF
The FIRE randomized clinical trial demonstrates that physiology-guided complete revascularization in patients aged 75 and older with myocardial infarction and multivessel disease maintains significant reductions in death, MI, stroke, and he
A multidomain rehabilitation program combining cardiovascular risk control, dietary counseling, and exercise significantly lowers the risk of cardiovascular death or unplanned hospitalization within one year in older myocardial infarction s
Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy conside
Post hoc analysis of the REBOOT trial shows that withholding or withdrawing beta blockers after myocardial infarction in patients with preserved LVEF (>40%) does not increase short-term or recurrent ischaemic events, challenging current
The REBOOT trial reveals a sex-specific differential effect of beta-blockers after MI, showing increased harm in women with preserved LVEF, challenging current guideline recommendations.
Routine H. pylori screening after acute myocardial infarction does not significantly reduce upper gastrointestinal bleeding incidence; targeted screening in anemia or kidney failure subgroups may offer benefit.
In a large Swedish cluster-randomized trial, routine Helicobacter pylori screening after acute myocardial infarction did not significantly reduce upper gastrointestinal bleeding, though high-risk subgroups may benefit.
This comprehensive review synthesizes evidence on Tongxinluo’s mechanisms and clinical benefits in myocardial infarction, acute coronary syndrome, and ischemia, highlighting patient subgroup analyses and current gaps in clinical evidence.
The MINT trial reveals that liberal transfusion strategies in MI patients with anemia, including those with heart failure, reduce adverse outcomes compared to restrictive transfusion, supporting a tailored approach to transfusion management
Coronary CTA, guided by clinical risk models and advanced radiomic plaque analysis, improves prediction and prevention of myocardial infarction in patients with new-onset chest pain, particularly in those with low clinical likelihood of cor
This study assesses the impact of β-blocker interruption on blood pressure and heart rate following myocardial infarction, revealing significant increases associated with treatment cessation, particularly in hypertensive patients.
Audit reveals major misclassification in hospital coding for myocardial infarction types, risking flawed epidemiology, reimbursement, and patient care.
